 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
 | |
| Industry | Healthcare' Pharmaceuticals |
|---|---|
| Founded | 1992 |
| Defunct | 2012 |
| Fate | acquired by GlaxoSmithKline |
| Headquarters | Rockville, Maryland, U.S. |
Key people | H. Thomas Watkins, CEO & Pres |
| Products | Diagnostic Substances |
Number of employees | 1000 |
| Website | www.hgsi.com |
Human Genome Sciences (HGS) was a biopharmaceutical corporation founded in 1992 by Craig Venter, Alan Walton and Wally Steinberg. It uses the human DNA sequence to develop protein and antibody drugs. It had drugs under development to treat such diseases as hepatitis C, systemic lupus erythmatosis, anthrax, and cancer. It collaborated with other biotechnology and pharmaceutical companies for development partnerships and licensing.[1]
On July 16, 2012, HGS agreed to be purchased by GlaxoSmithKline for $3.6 billion.[2]
- ^ Human Genome Sciences Announces 2008 Goals and Reports Substantial Progress Toward Commercialization at JPMorgan Healthcare Conference
- ^ Overly, Steven. "GlaxoSmithKline buys Human Genome Sciences for $3.6B." Washington Post. July 16, 2012. Accessed 2012-07-16.